arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Nexentis Technologies Inc.

NXTS
$1.44 ▲ +0.05 (+3.60%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
32 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
42
Health
Weak
Neutral
auto_awesome

Analytical Summary

Nexentis Technologies Inc. shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $1.2M
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC -98.2%
FCF / Share $-0.66
Trailing P/E
Price / Book 1.1x
FCF Yield
Debt / Equity 0.11
info Valuation on last close. End-of-day price, Sep 23, 2026.

32-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$2.00K
↓ -78.0%
Net Income Profit after all expenses
$-11.14M
↓ -147.2%
Operating Margin Operating profit as % of sales
-200.6%
↓ -123.1%
FCF / Share Free cash flow per share
$-0.66
↑ +72.8%
Long-Term Debt Long-term obligations
$16.06K
↑ +69.9%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
25
Financial Health
52
Cash Quality
63

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 8 years · 32 quarters